200 related articles for article (PubMed ID: 20872286)
21. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum.
Storr SJ; Royle L; Chapman CJ; Hamid UM; Robertson JF; Murray A; Dwek RA; Rudd PM
Glycobiology; 2008 Jun; 18(6):456-62. PubMed ID: 18332077
[TBL] [Abstract][Full Text] [Related]
22. O-linked mucin-type glycosylation regulates the transcriptional programme downstream of EGFR.
Tajadura-Ortega V; Gambardella G; Skinner A; Halim A; Van Coillie J; Schjoldager KTG; Beatson R; Graham R; Achkova D; Taylor-Papadimitriou J; Ciccarelli FD; Burchell JM
Glycobiology; 2021 Apr; 31(3):200-210. PubMed ID: 32776095
[TBL] [Abstract][Full Text] [Related]
23. N-Glycosylation of the MUC1 mucin in epithelial cells and secretions.
Parry S; Hanisch FG; Leir SH; Sutton-Smith M; Morris HR; Dell A; Harris A
Glycobiology; 2006 Jul; 16(7):623-34. PubMed ID: 16585136
[TBL] [Abstract][Full Text] [Related]
24. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
25. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas.
Burchell J; Poulsom R; Hanby A; Whitehouse C; Cooper L; Clausen H; Miles D; Taylor-Papadimitriou J
Glycobiology; 1999 Dec; 9(12):1307-11. PubMed ID: 10561455
[TBL] [Abstract][Full Text] [Related]
26. MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation.
Hanisch FG; Stadie TR; Deutzmann F; Peter-Katalinic J
Eur J Biochem; 1996 Feb; 236(1):318-27. PubMed ID: 8617281
[TBL] [Abstract][Full Text] [Related]
27. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
Oncogene; 2017 Nov; 36(46):6391-6407. PubMed ID: 28745318
[TBL] [Abstract][Full Text] [Related]
28. Identification and functional characterization of a human GalNAc [alpha]2,6-sialyltransferase with altered expression in breast cancer.
Sotiropoulou G; Kono M; Anisowicz A; Stenman G; Tsuji S; Sager R
Mol Med; 2002 Jan; 8(1):42-55. PubMed ID: 11984005
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma.
McGuckin MA; Hurst TG; Ward BG
Int J Cancer; 1995 Nov; 63(3):412-8. PubMed ID: 7591241
[TBL] [Abstract][Full Text] [Related]
30. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles.
Engelmann K; Kinlough CL; Müller S; Razawi H; Baldus SE; Hughey RP; Hanisch FG
Glycobiology; 2005 Nov; 15(11):1111-24. PubMed ID: 15972891
[TBL] [Abstract][Full Text] [Related]
31. Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line.
Wang F; Li Q; Ni W; Fang F; Sun X; Xie F; Wang J; Wang F; Gao S; Tai G
Oncol Rep; 2013 Jul; 30(1):260-8. PubMed ID: 23633115
[TBL] [Abstract][Full Text] [Related]
32. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
Ciborowski P; Finn OJ
Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
[TBL] [Abstract][Full Text] [Related]
33. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
34. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.
Suzuki Y; Sutoh M; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Habuchi T; Arai Y; Fukuda M; Ohyama C; Tsuboi S
Int J Oncol; 2012 Jun; 40(6):1831-8. PubMed ID: 22446589
[TBL] [Abstract][Full Text] [Related]
35. Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis.
Radhakrishnan P; Grandgenett PM; Mohr AM; Bunt SK; Yu F; Chowdhury S; Hollingsworth MA
Int J Cancer; 2013 Dec; 133(12):2824-33. PubMed ID: 23754791
[TBL] [Abstract][Full Text] [Related]
36. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
[TBL] [Abstract][Full Text] [Related]
37. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
38. Evidence for core 2 to core 1 O-glycan remodeling during the recycling of MUC1.
Razawi H; Kinlough CL; Staubach S; Poland PA; Rbaibi Y; Weisz OA; Hughey RP; Hanisch FG
Glycobiology; 2013 Aug; 23(8):935-45. PubMed ID: 23640779
[TBL] [Abstract][Full Text] [Related]
39. Expression of mucin antigens in human cancers and its relationship with malignancy potential.
Yonezawa S; Sato E
Pathol Int; 1997 Dec; 47(12):813-30. PubMed ID: 9503463
[TBL] [Abstract][Full Text] [Related]
40. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
